Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Telehealth brand Hims & Hers donated $1 million to President-elect Donald Trump's inaugural committee, the company told Axios ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new document replaces an earlier draft guidance issued in February 2007. The new ...

From weight loss to cancer drugs, subcutaneous injections are popular with patients for their convenience, potentially ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

The FDA published its first draft guidance on the use of AI in the development of drugs and biological products ...